Your browser doesn't support javascript.
loading
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann, Irmgard; Baum, Anke; Hofmann, Marco H; Trapani, Francesca; Reichel-Voda, Claudia; Ehrensperger, Diane; Aichinger, Martin; Ebner, Florian; Budano, Nicole; Schweifer, Norbert; Sykora, Martina; Depla, Erik; Boucneau, Joachim; Gschwind, Andreas; Kraut, Norbert; Hilberg, Frank; Künkele, Klaus-Peter.
Afiliação
  • Hofmann I; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Baum A; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Hofmann MH; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Trapani F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Reichel-Voda C; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Ehrensperger D; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Aichinger M; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Ebner F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Budano N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Schweifer N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Sykora M; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Depla E; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Boucneau J; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Gschwind A; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Kraut N; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Hilberg F; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
  • Künkele KP; Cancer Immunology and Immune Modulation (I.H., C.R.-V., M.S.), Cancer Pharmacology and Disease Positioning (A.B., M.H.H., M.A., F.E., F.H.), Cancer Research (D.E., A.G., N.K., K.-P.K.), and Oncology Translational Sciences (F.T., N.B., N.S.), Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
J Pharmacol Exp Ther ; 384(3): 331-342, 2023 03.
Article em En | MEDLINE | ID: mdl-36241203
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator A de Crescimento do Endotélio Vascular / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator A de Crescimento do Endotélio Vascular / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article